Fraxinellone treatment increases ROS (reactive oxygen species) levels in GBM cells, likely linked to SIRT3 downregulation, contributing to the apoptosis of GBM cells induced by fraxinellone [91]. This evidence concerns the gene SIRT3 and glioblastoma.